Comb in a tio n Ch em o therapy with Cis-Dia m m in e dic h lo ropla tin um , On c o vin , an d Bleo m ycin (COB) in Advanced Head and Neck Cancer Phase I1 MAGID H. AMER, MD, FRCS (ENG.), FRCP(C),\* RONALD M. IZBICKI, DO,\* V. K. VAITKEVICIUS, MD, FACP,t AND MUHYI AL-SARRAF, MD, FRCP(C), FACP\* Twen
Combination chemotherapy with vinblastine, bleomycin, and cis-diamminedichloroplatinum (ii) in squamous cell carcinoma of the head and neck
โ Scribed by Archie W. Brown Jr.; Johannes Blom; William M. Butler; Guillermo Garcia-Guerrero; Madison F. Richardson; Robert L. Henderson
- Publisher
- John Wiley and Sons
- Year
- 1980
- Tongue
- English
- Weight
- 565 KB
- Volume
- 45
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
A combination of cisplatin, methotrexate, bleomycin, and vincristine (CABO) was assessed in advanced epidermoid head and neck cancer. Among 72 patients with recurrent or metastatic disease and measurable lesions, there were 9 complete and 27 partial responses for an overall response rate of 50%. The
## For the EORTC Head and Neck Cooperative Group A total of 185 eligible patients with advanced inoperable squamous cell carcinoma of the head and neck were randomized into two groups; the cisplatin, methotrexate, bleomycin, and vincristine (CABO) group received cisplatin (50 mg/m2; day 4), methot
Forty-two patients with recurrent or metastatic squamous cell carcinoma of the head and neck were treated with vinblastine, bleomycin, and cisplatin. All patients had received prior surgery, radiation or chemotherapy and all had measurable disease. Forty-five percent of the patients responded with a